WO2024027901 - PREDICTIVE BIOMARKER OF CLINICAL RESPONSE TO A PDE4 INHIBITOR
National phase entry is expected:
Publication Number
WO/2024/027901
Publication Date
08.02.2024
International Application No.
PCT/EP2022/071618
International Filing Date
02.08.2022
Title **
[English]
PREDICTIVE BIOMARKER OF CLINICAL RESPONSE TO A PDE4 INHIBITOR
[French]
BIOMARQUEUR PRÉDICTIF DE RÉPONSE CLINIQUE À UN INHIBITEUR DE PDE4
Applicants **
CHIESI FARMACEUTICI S.P.A.
Inventors
GOVONI, Mirco
SANTORO, Debora
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2106 | |
| EPO | Filing, Examination, Granting | 9928 | |
| Japan | Filing, Examination, Granting | 2274 | |
| South Korea | Filing, Examination, Granting | 2107 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,155
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to the use of IL-8 as a biomarker of clinical response to a compound of formula (I), (I). It refers to a compound of formula (I) or a pharmaceutical composition thereof for use in a method of treatment of a disorder susceptible to treatment with a PDE4 inhibitor, wherein the method comprises the step of measuring the value of IL-8 in the blood of a subject and to a method to identify a subject to be treated with a compound of formula (I) or a pharmaceutical composition.[French]
La présente invention concerne l'utilisation de l'IL-8 comme biomarqueur de réponse clinique à un composé de formule (I), (I). L'invention concerne un composé de formule (I) ou une composition pharmaceutique associée destiné(e) à être utilisé(e) dans une méthode de traitement d'un trouble sensible au traitement avec un inhibiteur de PDE4, ladite méthode comprenant l'étape de mesure de la valeur de l'IL-8 dans le sang d'un sujet, ainsi qu'une méthode d'identification d'un sujet à traiter avec un composé de formule (I) ou une composition pharmaceutique.